Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and clozapine

levofloxacin has been researched along with clozapine in 22 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(clozapine)		Trials
(clozapine)		Recent Studies (post-2010) (clozapine)
4,3465812,2099,6917473,148

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)clozapine (IC50)
Adenylate cyclase type 1 Rattus norvegicus (Norway rat)0.14
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)3.6
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.032
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)1.47
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.476
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.045
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.1233
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)0.1534
5-hydroxytryptamine receptor 1AHomo sapiens (human)0.15
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.031
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.013
Alpha-2A adrenergic receptorHomo sapiens (human)0.09
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)0.14
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.1534
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.0096
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)2
D(2) dopamine receptorHomo sapiens (human)0.2044
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.0886
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)0.0567
Alpha-2B adrenergic receptorHomo sapiens (human)0.023
Alpha-2C adrenergic receptorHomo sapiens (human)0.0079
DRattus norvegicus (Norway rat)1.066
D(3) dopamine receptorRattus norvegicus (Norway rat)0.9312
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)1.2695
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)3.5772
D(2) dopamine receptorBos taurus (cattle)1.804
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.078
D(1A) dopamine receptorHomo sapiens (human)0.107
D(4) dopamine receptorHomo sapiens (human)0.0796
Adenylate cyclase type 3Rattus norvegicus (Norway rat)0.14
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)3.5772
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)3.5772
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)0.0567
Sodium-dependent noradrenaline transporter Homo sapiens (human)1.47
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)5.7544
Histamine H2 receptorHomo sapiens (human)3.61
Alpha-1D adrenergic receptorHomo sapiens (human)0.035
D(1B) dopamine receptorRattus norvegicus (Norway rat)0.9312
Adenylate cyclase type 2Rattus norvegicus (Norway rat)0.14
Adenylate cyclase type 4Rattus norvegicus (Norway rat)0.14
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.0658
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.0658
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)0.373
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)0.587
D(4) dopamine receptorRattus norvegicus (Norway rat)0.9312
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)0.587
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.0338
Histamine H1 receptorRattus norvegicus (Norway rat)0.023
Sodium-dependent serotonin transporterHomo sapiens (human)0.546
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)0.028
5-hydroxytryptamine receptor 2AMus musculus (house mouse)0.028
Histamine H1 receptorHomo sapiens (human)0.0049
D(3) dopamine receptorHomo sapiens (human)0.354
Adenylate cyclase type 8Rattus norvegicus (Norway rat)0.14
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.081
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)0.0567
5-hydroxytryptamine receptor 6Homo sapiens (human)0.0171
D(2) dopamine receptorMus musculus (house mouse)0.29
D(2) dopamine receptorRattus norvegicus (Norway rat)0.6759
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)3.6
5-hydroxytryptamine receptor 2BMus musculus (house mouse)0.028
Adenylate cyclase type 6Rattus norvegicus (Norway rat)0.14
Adenylate cyclase type 5Rattus norvegicus (Norway rat)0.14
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1.4162
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)3.6
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)3.6
5-hydroxytryptamine receptor 1AMus musculus (house mouse)2
Adenylyl cyclase 7 Rattus norvegicus (Norway rat)0.14
DBos taurus (cattle)4.09

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (40.91)29.6817
2010's13 (59.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keserü, GM1
Nagashima, R; Nishikawa, T; Tobita, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Glen, RC; Lowe, R; Mitchell, JB1
Gozalbes, R; Pineda-Lucena, A1
Ekins, S; Williams, AJ; Xu, JJ1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for levofloxacin and clozapine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

21 other study(ies) available for levofloxacin and clozapine

ArticleYear
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
QSAR-based solubility model for drug-like compounds.
    Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19

    Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors

2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014